Budigalimab — Drug Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

5 Recruiting

4 Completed trials

2 Sponsors

10 Countries

Phase II/III

Phase II

Phase I/II

Phase I

Phase II/III: 2 Phase II: 5 Phase I/II: 1 Phase I: 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Indications tested

HIV infection 1 Non-small cell lung cancer stage IV 1 Non-small cell lung cancer stage IIIB 1 Non-small cell lung cancer metastatic 1 Non-small cell lung cancer 1

Sponsors using this IMP

AbbVie Deutschland GmbH & Co. KG 8 Trishula Therapeutics Inc. 1

All trials

9 total

A Study to Assess Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Adult Participants with Metastatic Urothelial Carcino… Recruiting

2024-515506-11-00 Phase II 4 countries AbbVie Deutschland GmbH & Co. KG
A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Fluorouracil, … Recruiting

2024-513008-32-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting

2024-514465-18-00 Phase I/II 7 countries AbbVie Deutschland GmbH & Co. KG
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem… Recruiting

2023-505773-32-00 Phase II/III 4 countries AbbVie Deutschland GmbH & Co. KG
Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Recruiting

2023-504600-28-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co… Ended

2022-502948-13-00 Phase II 3 countries Abbvie Deutschland GmbH & Co. KG
Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Sub… Ended

2023-508281-15-00 Phase I 6 countries AbbVie Deutschland GmbH & Co. KG
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig… Ended

2023-508356-19-00 Phase II 4 countries Trishula Therapeutics Inc.
HIV: Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Ended

2023-505900-53-00 Phase II 7 countries AbbVie Deutschland GmbH & Co. KG

Showing 1–9 of 9 trials

← All drugs A–Z